Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety,Usability and Compliance of Using C-Scan System for Providing Information on Colonic Polypoid Lesions and Masses (C-Scan)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03735407
Recruitment Status : Recruiting
First Posted : November 8, 2018
Last Update Posted : June 4, 2019
Sponsor:
Information provided by (Responsible Party):
Ceck Cap Ltd.

Brief Summary:

Protocol Title: Evaluation of safety, usability and subject compliance while using Check- Cap's C-Scan System for providing structural information on colonic polypoid lesions and masses Study Design: Prospective, Multi-center, Single-arm, safety study Purpose: To demonstrate the safety of the Check-Cap C-Scan System Study Centers: Up to two (2) centers located in the United States Number of Participants: 45 healthy subjects Investigational Device: Check-Cap's C-Scan System comprises C-Scan Capsule, C-Scan Track and C-Scan View.

Primary Objective: To evaluate the safety of the Check-Cap C-Scan System Secondary Objectives: a. To evaluate subject's compliance b. To evaluate subject's satisfaction c. To collect data to improve the product's algorithm


Condition or disease Intervention/treatment Phase
Colo-rectal Cancer Device: C-Scan procedure Not Applicable

  Hide Detailed Description

Detailed Description:

Overall Design: Up to 45 healthy subjects will participate in this study. Subjects to be enrolled in this study are indicated and scheduled to undergo optical colonoscopy based on the following symptoms or by being classified as higher than average risk based on one or more of the following:

  • Surveillance - Significant findings in previous optical colonoscopy
  • Diagnostic - Polyps detected in virtual colonoscopy referred for polypectomy
  • Diagnostic - Polyps detected in previous optical colonoscopy (community setting) referred for polypectomy
  • Diagnostic - Positive FIT (Fecal Immunochemical Test)
  • Diagnostic - one or more of the typical symptoms:
  • abdominal pain
  • Change in bowel habits
  • Anemia or overt bleeding in stool
  • Significant weight loss
  • First degree relatives of CRC (Colo-Rectal Cancer)subjects Alternatively, average risk based on their age and demographics referred for screening for polyps

Each subject will receive a comprehensive explanation regarding the study nature. During this process, and per ethical committee approval, subjects may be asked several questions (over the phone) regarding their medical background for preliminary assessment of eligibility. Once informed consent is obtained, a thorough evaluation of subject's eligibility will be performed based on inclusion / exclusion criteria.

Eligible subjects will be required to undergo FIT procedure, per package insert instructions, within pre-defined timelines. All subjects will be scheduled to undergo capsule procedure, to be followed later on with optical colonoscopy procedure.

One to three days following end of C-Scan procedure the subjects will be contacted by phone by the clinical coordinator to follow-up on the subject well-being. Same follow-up procedures will be applied one to three days following Optical Colonoscopy procedure. Medical history and concomitant medication information will be collected for all subjects.

Study Duration: The duration of study participation for each subject is expected to be approximately 8-10 weeks. The total study duration across all patients is expected to be approximately 6 months, dependent upon subject recruitment rate.

C-Scan Procedure: Subjects will be instructed to skip breakfast or lunch on the day of C-Scan Capsule ingestion to expedite gastric passage. Liquids are allowed.

The subjects will be connected to the C-Scan Track and after successful system's activation (BIT - built in test), the subject will be asked to ingest the C-Scan Capsule with some water, contrast media (GE Omnipaque 350) and non-soluble fiber, in the presence of a physician investigator or designee. The subject will also be provided with an RF watch. A representative of the sponsor will attend the ingestion procedure, as needed to assure proper activation.

Post ingestion, the subject will receive detailed instructions about the daily routine and activities as well as use of the RF watch and then will be discharged home with written instructions on the procedure Instructions for use (IFU), daily diary, FIT kit and capsule return kit.

FIT Procedure: All subjects will be required to perform FIT procedure using [OC-Light] FIT Kit prior or during the capsule procedure Capsule Return: Capsule procedure is completed upon capsule excretion or system auditory indication of 'End of Procedure'. Subjects will be instructed to inform the study coordinator or designee upon capsule excretion


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 45 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Prospective, Multi-center, Single-arm, safety study
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Evaluation of Safety, Usability and Subject Compliance While Using Check- Cap's C-Scan System for Providing Structural Information on Colonic Polypoid Lesions and Masses
Actual Study Start Date : February 1, 2019
Estimated Primary Completion Date : August 1, 2019
Estimated Study Completion Date : September 1, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Nuclear Scans

Arm Intervention/treatment
Experimental: C-Scan procedure
Subjects who are at high or at average risk for developing CRC and who are scheduled for optical colonoscopy will undergo C-Scan procedure
Device: C-Scan procedure

The subjects will be connected to the C-Scan Track and after successful system's activation. The subject will be asked to ingest the C-Scan Capsule with some water, contrast media The subject will be required to ingest daily dose (3 X 15 ml) of contrast media. Capsule procedure is completed upon capsule excretion.

o Collecting procedure related data: Technical performance in normal daily routine, Segmental transit time,Procedure duration, Number of Bowel movements , Similarity between C-Scan results and colonoscopy Etc,

Other Name: data collection to improve the product's algorithm




Primary Outcome Measures :
  1. Number of incidence of device and procedure related Serious Adverse Events (SAE) [ Time Frame: 6 Months ]
    The safety of the Check-Cap System will be evaluated by the incidence of device and procedure related Serious Adverse Events (SAE), as adjudicated by the Independent Physician Adjudicator.


Secondary Outcome Measures :
  1. Non-compliance rate of subjects (%) [ Time Frame: 6 months ]

    Subject compliance will be assessed by

    - Non-compliance rate throughout the study via diary completion by the subject Specific questionnaire. completed by remote subject monitoring (via telephone) The rate will be measured in a percentage scale (1-100%) Score less then 50% will be considered as a compliance failure


  2. To evaluate subject's satisfaction [ Time Frame: 8 weeks ]

    Subject satisfaction will be established by:

    Designated questionnaire that focuses on patient's impressions regarding tolerance and potential safety concerns, which will be provided to the subjects after the C-Scan procedure and after the colonoscopy procedure. Acceptance criteria was defined as average score >3.5 (1- low satisfaction to 5- high satisfaction), which represent high satisfaction with the safety and tolerance of the C-scan system.

    Comparing patient's satisfaction with C-Scan procedure and colonoscopy procedure




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male or female at the age of 40-80 years' old.
  2. Subject provided signed informed consent.
  3. Subject is willing and able to comply with the specified study requirements and follow-up evaluations, and can be contacted by telephone.
  4. Subjects able and agrees to undergo colonoscopy procedure.
  5. BMI > 22 and ≤ 35.
  6. Maximum body (abdominal) circumference < 120 cm.
  7. Has at least 3 bowel movements per week
  8. A colonoscopy procedure is pre-scheduled within 60 days

Exclusion Criteria:12.3 Exclusion Criteria

  1. Known history of dysphagia or other swallowing disorders.
  2. History of the followings: Inflammatory Bowel Disease (IBD) including Crohn's disease or Ulcerative, Colitis, Meckel's Diverticulum, Bowen Hernia, known fistulas or strictures (doctors' discretion), or a history of small bowel obstruction.
  3. Known motility disorders:

i. Chronic Constipation: less than 3 bowel movements/week, w/out the use of laxatives.

ii. Delayed gastric emptying. iii. Narcotic use d. Prior history of abdominal surgery that might cause bowel strictures leading to capsule retention, as determined by physician discretion with the exception of appendectomy, cholecystectomy and hysterectomy e. Any condition believed to have an increased risk for capsule retention, strictures, bowel adhesion or other obstacles to free passage of the capsule (such as intestinal tumors, radiation enteritis) or incomplete colonoscopies (e.g. due to obstructions or NSAID enteropathy) as determined by physician discretion.

f. Has a cardiac device (e.g. pacemaker or ICD-Implantable Cardioverter Defibrillator) or any other active implanted device g. Known sensitivity to iodine, or with known kidney failure. h. Known condition which precludes compliance or is contraindicated with study and/or device instructions.

i. Has a Magnetic Image Resonance (MRI) procedure scheduled within 1 month j. Known condition of drug abuse and/or alcoholism. k. Women who are either pregnant or nursing at the time of screening (to be verified by urine or serum pregnancy test for woman of child- bearing potential who are not post-menopausal or undergone surgical sterilization.

l. Concurrent participation in another clinical trial using any investigational drug or device.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03735407


Contacts
Layout table for location contacts
Contact: Christopher Hawryluk, CRC 1-6465017984 Christopher.Hawryluk@nyulangone.org
Contact: Seth Gross, MD 1-6465017984 Seth.Gross@nyulangone.org

Locations
Layout table for location information
United States, Minnesota
Mayoclinic Recruiting
Rochester, Minnesota, United States, 55905
Contact: Crystal Tholen, CRC    507-538-1361    tholen.crystal@mayo.edu   
Contact: Elizabeth Rajan, Prof. PI    507)538-1361      
Sponsors and Collaborators
Ceck Cap Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Seth Gross NYU Langone Health

Layout table for additonal information
Responsible Party: Ceck Cap Ltd.
ClinicalTrials.gov Identifier: NCT03735407     History of Changes
Other Study ID Numbers: CL-SY-02-0096
First Posted: November 8, 2018    Key Record Dates
Last Update Posted: June 4, 2019
Last Verified: May 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Rectal Diseases
Colonic Diseases